Clene (CLNN) Stock Forecast, Price Target & Predictions
CLNN Stock Forecast
Clene stock forecast is as follows: an average price target of $10.00 (represents a 76.37% upside from CLNN’s last price of $5.67) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
CLNN Price Target
CLNN Analyst Ratings
Clene Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
May 02, 2022 | Sumant Kulkarni | Canaccord Genuity | $10.00 | $2.93 | 241.30% | 76.37% |
Clene Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $5.67 | $5.67 | $5.67 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 04, 2024 | Canaccord Genuity | Buy | Buy | Hold |
Sep 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 10, 2024 | EF Hutton | - | Buy | Initialise |
Aug 06, 2024 | Rodman & Renshaw | Buy | Buy | Hold |
Aug 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
May 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Apr 17, 2024 | Benchmark | Underperform | Underperform | Hold |
Apr 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Mar 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Clene Financial Forecast
Clene Revenue Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $170.00K | $108.00K | - | $107.00K | $234.00K | $174.00K | $35.00K | $30.00K | $199.00K | $110.00K |
Avg Forecast | $256.74K | $242.37K | $228.80K | $215.98K | $203.89K | $192.47K | $181.70K | $171.52K | $161.92K | $152.85K | $144.29K | $136.21K | $50.00K | $50.00K | $50.00K | $50.00K | $143.33K | $106.67K | $120.00K | $162.50K | $145.00K | $136.00K | $117.83K | $134.17K | $181.00K | $86.67K | $83.33K | $83.00K | $116.25K | $116.25K |
High Forecast | $256.74K | $242.37K | $228.80K | $215.98K | $203.89K | $192.47K | $181.70K | $171.52K | $161.92K | $152.85K | $144.29K | $136.21K | $50.00K | $50.00K | $50.00K | $50.00K | $143.33K | $106.67K | $120.00K | $162.75K | $165.71K | $136.00K | $117.83K | $134.17K | $181.00K | $86.67K | $83.33K | $83.00K | $116.25K | $116.25K |
Low Forecast | $256.74K | $242.37K | $228.80K | $215.98K | $203.89K | $192.47K | $181.70K | $171.52K | $161.92K | $152.85K | $144.29K | $136.21K | $50.00K | $50.00K | $50.00K | $50.00K | $143.33K | $96.97K | $120.00K | $162.25K | $124.28K | $136.00K | $117.83K | $134.17K | $181.00K | $86.67K | $83.33K | $83.00K | $116.25K | $116.25K |
# Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 0.79% | - | 0.80% | 1.29% | 2.01% | 0.42% | 0.36% | 1.71% | 0.95% |
Clene EBITDA Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-9.51M | $-9.54M | - | $-10.24M | $-10.21M | $-8.24M | $-12.89M | $-12.71M | $4.80M | $29.19M |
Avg Forecast | $-154.04K | $-145.42K | $-137.28K | $-129.59K | $-122.33K | $-115.48K | $-109.02K | $-102.91K | $-97.15K | $-91.71K | $-86.58K | $-81.73K | $-30.00K | $-30.00K | $-30.00K | $-30.00K | $-86.00K | $-64.00K | $-72.00K | $-97.50K | $-87.00K | $-81.60K | $-70.70K | $-80.50K | $-108.60K | $-52.00K | $-50.00K | $-10.00 | $-69.75K | $-69.75K |
High Forecast | $-154.04K | $-145.42K | $-137.28K | $-129.59K | $-122.33K | $-115.48K | $-109.02K | $-102.91K | $-97.15K | $-91.71K | $-86.58K | $-81.73K | $-30.00K | $-30.00K | $-30.00K | $-30.00K | $-86.00K | $-58.18K | $-72.00K | $-97.35K | $-74.57K | $-81.60K | $-70.70K | $-80.50K | $-108.60K | $-52.00K | $-50.00K | $-8.00 | $-69.75K | $-69.75K |
Low Forecast | $-154.04K | $-145.42K | $-137.28K | $-129.59K | $-122.33K | $-115.48K | $-109.02K | $-102.91K | $-97.15K | $-91.71K | $-86.58K | $-81.73K | $-30.00K | $-30.00K | $-30.00K | $-30.00K | $-86.00K | $-64.00K | $-72.00K | $-97.65K | $-99.43K | $-81.60K | $-70.70K | $-80.50K | $-108.60K | $-52.00K | $-50.00K | $-13.00 | $-69.75K | $-69.75K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 109.29% | 116.94% | - | 127.20% | 94.04% | 158.44% | 257.85% | 1271000.00% | -68.85% | -418.49% |
Clene Net Income Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-10.17M | $-2.42M | - | $-13.87M | $8.62M | $-12.13M | $3.90M | $-14.08M | $4.42M | $28.94M |
Avg Forecast | $-24.32M | $-21.93M | $-20.37M | $-21.48M | $-30.02M | $-27.07M | $-25.15M | $-26.51M | $-29.83M | $-26.90M | $-24.99M | $-41.39M | $-79.44M | $-87.78M | $-88.69M | $-90.96M | $-123.63M | $-170.93M | $-193.77M | $-205.54M | $-184.99M | $-231.23M | $-316.86M | $-372.09M | $-88.09M | $-554.23M | $-515.74M | $-11.00 | $-416.22M | $-518.99M |
High Forecast | $-24.32M | $-21.93M | $-20.37M | $-21.48M | $-30.02M | $-27.07M | $-25.15M | $-26.51M | $-29.83M | $-26.90M | $-24.99M | $-41.39M | $-79.44M | $-87.78M | $-88.69M | $-90.96M | $-123.63M | $-168.38M | $-193.77M | $-205.54M | $-158.56M | $-231.23M | $-316.86M | $-372.09M | $-88.09M | $-554.23M | $-515.74M | $-9.00 | $-416.22M | $-518.99M |
Low Forecast | $-24.32M | $-21.93M | $-20.37M | $-21.48M | $-30.02M | $-27.07M | $-25.15M | $-26.51M | $-29.83M | $-26.90M | $-24.99M | $-41.39M | $-79.44M | $-87.78M | $-88.69M | $-90.96M | $-123.63M | $-172.21M | $-193.77M | $-205.54M | $-211.41M | $-231.23M | $-316.86M | $-372.09M | $-88.09M | $-554.23M | $-515.74M | $-14.00 | $-416.22M | $-518.99M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | 0.01% | - | 0.04% | -0.10% | 0.02% | -0.01% | 1280181.82% | -0.01% | -0.06% |
Clene SG&A Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.32M | $3.67M | - | $3.18M | $4.26M | $3.34M | $4.19M | $4.38M | $2.07M | $4.40M |
Avg Forecast | $5.62M | $5.31M | $5.01M | $4.73M | $4.46M | $4.21M | $3.98M | $3.76M | $3.54M | $3.35M | $3.16M | $2.98M | $1.09M | $1.09M | $1.09M | $1.09M | $3.14M | $2.34M | $2.63M | $3.56M | $3.17M | $2.98M | $2.58M | $2.94M | $3.96M | $1.90M | $1.82M | $4.00 | $2.55M | $2.55M |
High Forecast | $5.62M | $5.31M | $5.01M | $4.73M | $4.46M | $4.21M | $3.98M | $3.76M | $3.54M | $3.35M | $3.16M | $2.98M | $1.09M | $1.09M | $1.09M | $1.09M | $3.14M | $2.34M | $2.63M | $3.56M | $3.63M | $2.98M | $2.58M | $2.94M | $3.96M | $1.90M | $1.82M | $5.00 | $2.55M | $2.55M |
Low Forecast | $5.62M | $5.31M | $5.01M | $4.73M | $4.46M | $4.21M | $3.98M | $3.76M | $3.54M | $3.35M | $3.16M | $2.98M | $1.09M | $1.09M | $1.09M | $1.09M | $3.14M | $2.12M | $2.63M | $3.55M | $2.72M | $2.98M | $2.58M | $2.94M | $3.96M | $1.90M | $1.82M | $3.00 | $2.55M | $2.55M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.23% | - | 1.08% | 1.07% | 1.76% | 2.30% | 1093750.00% | 0.81% | 1.73% |
Clene EPS Forecast
Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.08 | $-0.02 | - | $-0.18 | $0.13 | $-0.19 | $0.06 | $-0.22 | $0.07 | $0.47 |
Avg Forecast | $-0.19 | $-0.17 | $-0.16 | $-0.17 | $-0.23 | $-0.21 | $-0.20 | $-0.21 | $-0.23 | $-0.21 | $-0.19 | $-0.32 | $-0.62 | $-0.68 | $-0.69 | $-0.71 | $-0.96 | $-1.33 | $-1.51 | $-1.60 | $-1.44 | $-1.80 | $-2.47 | $-2.90 | $-0.69 | $-4.31 | $-4.01 | $-3.90 | $-3.24 | $-4.04 |
High Forecast | $-0.19 | $-0.17 | $-0.16 | $-0.17 | $-0.23 | $-0.21 | $-0.20 | $-0.21 | $-0.23 | $-0.21 | $-0.19 | $-0.32 | $-0.62 | $-0.68 | $-0.69 | $-0.71 | $-0.96 | $-1.31 | $-1.51 | $-1.60 | $-1.23 | $-1.80 | $-2.47 | $-2.90 | $-0.69 | $-4.31 | $-4.01 | $-3.90 | $-3.24 | $-4.04 |
Low Forecast | $-0.19 | $-0.17 | $-0.16 | $-0.17 | $-0.23 | $-0.21 | $-0.20 | $-0.21 | $-0.23 | $-0.21 | $-0.19 | $-0.32 | $-0.62 | $-0.68 | $-0.69 | $-0.71 | $-0.96 | $-1.34 | $-1.51 | $-1.60 | $-1.65 | $-1.80 | $-2.47 | $-2.90 | $-0.69 | $-4.31 | $-4.01 | $-3.90 | $-3.24 | $-4.04 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.06% | 0.01% | - | 0.06% | -0.19% | 0.04% | -0.02% | 0.06% | -0.02% | -0.12% |
Clene Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
SNSE | Sensei Biotherapeutics | $0.52 | $5.50 | 957.69% | Buy |
NKTX | Nkarta | $3.23 | $21.60 | 568.73% | Buy |
HOWL | Werewolf Therapeutics | $2.26 | $12.00 | 430.97% | Buy |
MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
KZR | Kezar Life Sciences | $7.09 | $17.50 | 146.83% | Buy |
IMNM | Immunome | $12.81 | $30.33 | 136.77% | Buy |
NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
FHTX | Foghorn Therapeutics | $8.24 | $16.33 | 98.18% | Buy |
CLNN | Clene | $5.67 | $10.00 | 76.37% | Buy |
GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
CLNN Forecast FAQ
Is Clene a good buy?
Yes, according to 6 Wall Street analysts, Clene (CLNN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CLNN's total ratings.
What is CLNN's price target?
Clene (CLNN) average price target is $10 with a range of $10 to $10, implying a 76.37% from its last price of $5.67. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Clene stock go up soon?
According to Wall Street analysts' prediction for CLNN stock, the company can go up by 76.37% (from the last price of $5.67 to the average price target of $10), up by 76.37% based on the highest stock price target, and up by 76.37% based on the lowest stock price target.
Can Clene stock reach $9?
CLNN's average twelve months analyst stock price target of $10 supports the claim that Clene can reach $9 in the near future.
What are Clene's analysts' financial forecasts?
Clene's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $749.58K (high $749.58K, low $749.58K), average EBITDA is $-450K (high $-450K, low $-450K), average net income is $-109M (high $-109M, low $-109M), average SG&A $16.41M (high $16.41M, low $16.41M), and average EPS is $-0.847 (high $-0.847, low $-0.847). CLNN's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $943.89K (high $943.89K, low $943.89K), average EBITDA is $-566K (high $-566K, low $-566K), average net income is $-88.1M (high $-88.1M, low $-88.1M), average SG&A $20.67M (high $20.67M, low $20.67M), and average EPS is $-0.686 (high $-0.686, low $-0.686).
Did the CLNN's actual financial results beat the analysts' financial forecasts?
Based on Clene's last annual report (Dec 2023), the company's revenue was $654K, beating the average analysts forecast of $533K by 22.70%. Apple's EBITDA was $-40.54M, beating the average prediction of $-320K by 12576.71%. The company's net income was $-49.504M, missing the average estimation of $-1.105B by -95.52%. Apple's SG&A was $14.42M, beating the average forecast of $11.67M by 23.55%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-8.603 by -99.99%. In terms of the last quarterly report (Dec 2023), Clene's revenue was $170K, beating the average analysts' forecast of $145K by 17.24%. The company's EBITDA was $-9.508M, beating the average prediction of $-87K by 10828.74%. Clene's net income was $-10.173M, missing the average estimation of $-185M by -94.50%. The company's SG&A was $3.32M, beating the average forecast of $3.17M by 4.64%. Lastly, the company's EPS was $-0.0792, missing the average prediction of $-1.44 by -94.50%